Nature-based Therapies in Stroke Rehabilitation
Nature-based Therapies Supporting Conventional Therapies in Promoting Stroke Rehabilitation: a Randomised Controlled Pilot Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hanna Haveri, MD PhD
- Phone Number: +358444828225
- Email: hanna.haveri@paijatha.fi
Study Contact Backup
- Name: Marja Mikkelsson, Prof
- Email: marja.mikkelsson@paijatha.fi
Study Locations
-
-
-
Lahti, Finland, 15850
- Recruiting
- Joint Authority for Päijät-Häme Social and Health Care
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Acute/Subacute stroke
- Rehabilitation ward patient
Exclusion Criteria:
- Incapable of independent decision making
- Traumatic bleeding in brain tissue
- Severe aphasia
- Severe, malign ongoing disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nature-based therapy intervention group
Patients getting additional therapies outdoors
|
Therapy sessions conducted outdoors
|
|
No Intervention: Control group
Patients getting additional rehabilitation tasks indoors
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional ability
Time Frame: 0-30 days
|
Evaluation of functional ability in intervention and control groups by Patient-Reported Outcomes Measurement Information (PROMIS) questionnaire
|
0-30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life by WHO Disability Assessment Schedule (WHODAS)
Time Frame: 0-30 days
|
Evaluation of quality of life in intervention and control groups, measured by WHODAS questionnaire.
|
0-30 days
|
|
Assessment of the intervention impacts on rehabilitation
Time Frame: 0-120 days
|
Evaluation of the impact of intervention into achieving the predetermined goals of rehabilitation.
Measured by Goal Attainment Scale (GAS) in intervention and control group.
|
0-120 days
|
|
Psychological or psychotherapeutic effects
Time Frame: 0-30 days
|
Evaluation of the effect of interventions to psychological well-being or psychotherapeutic effect in comparison to control groups.
Measurement by Core-10-survey.
|
0-30 days
|
|
Intervention effects on microbiome
Time Frame: 0-120 days
|
Measurement of the effect of intervention on participant microbiome compared to participant microbiome in the control group.
Microbial analyses of stool, saliva and flakes of skin.
|
0-120 days
|
|
Intervention effect on the activity of autonomic nerve system
Time Frame: 0-30 days
|
The activity of autonomic nerve system is measured with a portable device recording eg heart rate and activity.
The activity of autonomic nerve system is measured both in intervention and control group.
|
0-30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Hanna Haveri, MD PhD, Päijät-Hämeen Hyvinvointialue
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Q062
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.